13.61B
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI.

Similar securities

Based on sector and market capitalization

Report issue